| Table 1 |
Key Differences Between Current Guidelines (KDOQI Anemia 2006) and Previous Anemia Guidelines (KDOQI 2000 and EBPG 2004) |
| Table 2 |
Relationship Between Hb Level and Kidney Function |
| Table 3 |
Relationship Between Hct and Kidney Function |
| Table 4 |
Prevalence of Anemia by Level of Kidney Function |
| Table 5 |
Difference in Hb and Hct From Reference by Category of CCr |
| Table 6 |
Difference in Hb and Hct From Reference According to Category of BSA and Normalized eGFR |
| Table 7 |
Hb for Males by Race/Ethnicity and Age: United States, 1988 to 1994 |
| Table 8 |
Hb for Females by Race/Ethnicity and Age: United States, 1988 to 1994 |
| Table 9 |
Normal Increase in Hb Levels Related to Long-Term Altitude Exposure |
| Table 10 |
Maximum Hb Cutoff Values for Anemia in Pregnancy |
| Table 11 |
Adjustment to Hb for Smoking by Number of Packets per Day |
Table 12 |
RCTs Examining Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the HD-CKD and PD-CKD Populations |
| Table 13 |
RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the HD-CKD and PD-CKD Populations |
| Table 14 |
Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in HD-CKD and PD-CKD Populations: ESA versus ESA |
| Table 15 |
Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the HD-CKD and PD-CKD Populations: ESA versus Placebo |
| Table 16 |
Effects of Distinct Hb Targets/Levels on Key Clinical Outcomes in the ND-CKD Population |
| Table 17 |
RCTs Examining Effects of Distinct Hb Targets/Levels on QOL in the ND-CKD Population |
| Table 18 |
Non-CVD/Mortality AE Rates in RCTs Examining Distinct Hb Targets/Levels in the CKD Population |
| Table 19 |
RCTs Examining Effects of Distinct Hb Targets/Levels on Exercise Capacity in the HD-CKD and PD-CKD Populations |
| Table 20 |
Target Hb Levels in the HD-CKD and PD-CKD Populations |
| Table 21 |
Target Hb Levels in the ND-CKD Population |
| Table 22 |
Anemia Management Protocol Information for Initial Anemia Management Used in ESA RCTs |
| Table 23 |
RCTs for Ferritin and TSAT Targets in the HD-CKD Population |
| Table 24 |
Value of Baseline Ferritin for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population |
| Table 25 |
Value of Ferritin in Assessing Iron Storage Excess or Deficiency |
| Table 26 |
Value of Baseline TSAT for Assessing Likelihood of Response to IV Iron Therapy in the HD-CKD Population |
| Table 27 |
Value of Baseline CHr for Assessing Likelihood of Response to IV Iron Therapy |
| Table 28 |
Mean Monthly Dose of Iron in Adult Prevalent HD-CKD Patients on ESA Therapy |
| Table 29A |
Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations |
| Table 29B |
Comparative RCTs of IV versus PO Iron Administration and Efficacy of Anemia Management in the ND-CKD Population |
| Table 30 |
Comparative RCTs of PO Iron Administration versus Placebo/Control and Efficacy of Anemia Management in the HD-CKD and PD-CKD Populations |
| Table 31 |
Serious AEs of Iron Agents in Patients Naïve to Tested Iron Agent (N > 100) |
| Table 31A |
IV versus PO Iron Agents in the HD-CKD and PD-CKD Populations |
| Table 31B |
IV versus PO Iron Agents in the ND-CKD Population |
| Table 32 |
RCTs Evaluating Effects of Treatment with IV L-Carnitine on Hb Levels and ESA Doses in the HD-CKD Population |
| Table 33 |
Use of L-Carnitine as an Adjuvant to ESA Treatment in the HD-CKD Population |
| Table 34 |
RCTs Evaluating Effects of Treatment With IV Ascorbic Acid on Hb Levels and ESA Doses in the HD-CKD Population |
| Table 35 |
Use of Ascorbic Acid as an Adjuvant to ESA Treatments in the HD-CKD Population |
| Table 36 |
RCTs Evaluating Effects of Treatment With IM Androgens on Hb Levels in the HD-CKD Population |
| Table 37 |
Use of Androgens as an Adjuvant to ESA Treatment in the HD-CKD Population |
| Table 38 |
Published Experience in Patients With Anemia, CKD, and a Preexisting Hematologic Disorder |
| Table 39 |
Hb Levels (g/dL) in Children Between 1 and 19 Years for Initiation of Anemia Workup |
| Table 40 |
Hb Levels (g/dL) in Children Between Birth and 24 Months for Initiation of Anemia Workup |
| Table 41 |
Literature Review of Anemia in Transplant CKD: Key Conclusions |
| Table 42 |
Prevalance of PTA by Duration of Posttransplantation Period |
| Table 43 |
Example of a Summary Table |
| Table 44 |
Systematic Review Topics and Screening Criteria |
| Table 45 |
Literature Search Yield of Primary Articles for Systematic Review Topics |
| Table 45A |
Assessment of Study Applicability |
| Table 46 |
Details of First-Look Topics, Ovid Literature Searches, and Yield by Topic |
| Table 46A |
Grades for Study Quality |
| Table 47 |
Evaluation of Studies of Prevalence |
| Table 48 |
Format for Guidelines |
| Table 49 |
Balance of Benefit and Harm |
| Table 50 |
Definitions of Grades for Quality of Overall Evidence |
| Table 51 |
Example of an Evidence Profile |